Posted by Michael Wonder on 08 Jul 2024
Besremi retries for insurance coverage promising a potential operational cure
8 July 2024 - Besremi (rofeginterferon alfa-2b), which has recently set a new standard in treating polycythemia vera by offering a potential operational cure, is again seeking insurance coverage.
PharmaEssentia Korea's application for a new benefit for Besremi, submitted in March, will be reviewed on Wednesday by HIRA’s fifth Cancer Disease Review Committee.
